DF Dent & Co. Inc. Buys 6,134 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

DF Dent & Co. Inc. lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,170 shares of the company’s stock after buying an additional 6,134 shares during the quarter. DF Dent & Co. Inc.’s holdings in Medpace were worth $17,333,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in MEDP. Ameritas Investment Partners Inc. raised its stake in Medpace by 0.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 8,495 shares of the company’s stock valued at $1,597,000 after purchasing an additional 48 shares during the period. Creative Planning raised its stake in Medpace by 1.9% during the 2nd quarter. Creative Planning now owns 3,110 shares of the company’s stock valued at $465,000 after purchasing an additional 58 shares during the period. Procyon Advisors LLC raised its stake in Medpace by 5.8% during the 1st quarter. Procyon Advisors LLC now owns 1,307 shares of the company’s stock valued at $246,000 after purchasing an additional 72 shares during the period. Schulhoff & Co. Inc. raised its stake in Medpace by 3.7% during the 1st quarter. Schulhoff & Co. Inc. now owns 2,080 shares of the company’s stock valued at $391,000 after purchasing an additional 75 shares during the period. Finally, Meritage Portfolio Management raised its stake in Medpace by 4.4% during the 1st quarter. Meritage Portfolio Management now owns 1,883 shares of the company’s stock valued at $354,000 after purchasing an additional 80 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, General Counsel Stephen P. Ewald sold 21,850 shares of Medpace stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $254.39, for a total value of $5,558,421.50. Following the completion of the transaction, the general counsel now owns 14,854 shares in the company, valued at approximately $3,778,709.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Robert O. Kraft sold 13,782 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $265.67, for a total transaction of $3,661,463.94. Following the completion of the transaction, the director now owns 188 shares in the company, valued at approximately $49,945.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 21,850 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $254.39, for a total value of $5,558,421.50. Following the transaction, the general counsel now owns 14,854 shares of the company’s stock, valued at approximately $3,778,709.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,632 shares of company stock worth $11,004,885. 25.70% of the stock is currently owned by company insiders.

Medpace Stock Performance

NASDAQ:MEDP traded up $7.93 during trading hours on Monday, reaching $279.04. The stock had a trading volume of 169,205 shares, compared to its average volume of 332,603. The stock has a market capitalization of $8.53 billion, a PE ratio of 32.39 and a beta of 1.37. The company has a 50 day moving average price of $254.70 and a two-hundred day moving average price of $220.29. Medpace Holdings, Inc. has a 52 week low of $141.30 and a 52 week high of $280.00.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 24th. The company reported $1.93 EPS for the quarter, topping analysts’ consensus estimates of $1.90 by $0.03. The firm had revenue of $460.90 million during the quarter, compared to analysts’ expectations of $433.75 million. Medpace had a return on equity of 72.88% and a net margin of 16.06%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.46 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 8.39 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group lifted their target price on Medpace from $215.00 to $270.00 in a research note on Wednesday, July 26th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, September 2nd. Guggenheim lifted their price objective on Medpace from $252.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Finally, Robert W. Baird lifted their price objective on Medpace from $240.00 to $250.00 in a research note on Friday. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $264.33.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.